Acarix AB (publ) (ACARIX.ST)
SEK 0.22
(-2.47%)
SEK 0.22
(-2.47%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - SEK | 0.0% |
| 2022 | - SEK | -100.0% |
| 2021 | 239 Thousand SEK | -57.92% |
| 2020 | 568 Thousand SEK | 688.89% |
| 2019 | 72 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - SEK | 0.0% |
| 2024 Q1 | - SEK | 0.0% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 Q4 | - SEK | 0.0% |
| 2023 FY | - SEK | 0.0% |
| 2022 Q4 | - SEK | -100.0% |
| 2022 Q2 | 98 Thousand SEK | -42.01% |
| 2022 Q1 | 169 Thousand SEK | -29.29% |
| 2022 FY | - SEK | -100.0% |
| 2022 Q3 | 37 Thousand SEK | -62.24% |
| 2021 Q1 | 456 Thousand SEK | -19.72% |
| 2021 FY | 239 Thousand SEK | -57.92% |
| 2021 Q2 | 386 Thousand SEK | -15.35% |
| 2021 Q3 | 309 Thousand SEK | -19.95% |
| 2021 Q4 | 239 Thousand SEK | -22.65% |
| 2020 Q1 | 1 Million SEK | 1293.06% |
| 2020 FY | 568 Thousand SEK | 688.89% |
| 2020 Q2 | 806 Thousand SEK | -19.64% |
| 2020 Q3 | 616 Thousand SEK | -23.57% |
| 2020 Q4 | 568 Thousand SEK | -7.79% |
| 2019 Q4 | 72 Thousand SEK | -22.58% |
| 2019 FY | 72 Thousand SEK | 0.0% |
| 2019 Q3 | 93 Thousand SEK | -23.14% |
| 2019 Q2 | 121 Thousand SEK | -59.67% |
| 2019 Q1 | 300 Thousand SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ADDvise Group AB (publ) | 1.45 Billion SEK | 100.0% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 100.0% |
| Arcoma AB | 1.92 Million SEK | 100.0% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 100.0% |
| BICO Group AB (publ) | 1.75 Billion SEK | 100.0% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 100.0% |
| CellaVision AB (publ) | 28.66 Million SEK | 100.0% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | 100.0% |
| Chordate Medical Holding AB (publ) | - SEK | NaN% |
| C-Rad AB (publ) | 1.75 Million SEK | 100.0% |
| Duearity AB (publ) | 2.94 Million SEK | 100.0% |
| Dignitana AB (publ) | 6.07 Million SEK | 100.0% |
| Episurf Medical AB (publ) | 2.3 Million SEK | 100.0% |
| Getinge AB (publ) | 3.9 Billion SEK | 100.0% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 100.0% |
| Iconovo AB (publ) | 4.9 Million SEK | 100.0% |
| Integrum AB (publ) | 4.84 Million SEK | 100.0% |
| Luxbright AB (publ) | 206.02 Thousand SEK | 100.0% |
| Mentice AB (publ) | 2.14 Million SEK | 100.0% |
| OssDsign AB (publ) | 214 Thousand SEK | 100.0% |
| Paxman AB (publ) | 2.53 Million SEK | 100.0% |
| Promimic AB (publ) | - SEK | NaN% |
| Qlife Holding AB (publ) | 3 Million SEK | 100.0% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 100.0% |
| ScandiDos AB (publ) | - SEK | NaN% |
| Sectra AB (publ) | 19.2 Million SEK | 100.0% |
| Sedana Medical AB (publ) | 1.01 Million SEK | 100.0% |
| Senzime AB (publ) | 8.57 Million SEK | 100.0% |
| SpectraCure AB (publ) | 4.39 Million SEK | 100.0% |
| Stille AB | 38.06 Million SEK | 100.0% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 100.0% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 100.0% |